Search for other papers by Maximilian Bielohuby in
Google Scholar
PubMed
Search for other papers by Martin Bidlingmaier in
Google Scholar
PubMed
Search for other papers by Uwe Schwahn in
Google Scholar
PubMed
the same analyte between rodent assays from different vendors are documented throughout literature. For the purpose of this review, and using the analysis of FGF-15 in mice as one example, here we illustrate the significant performance differences
Division of Endocrinology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Search for other papers by Volha V Zhukouskaya in
Google Scholar
PubMed
APHP, Department of Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
Search for other papers by Anya Rothenbuhler in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
IRCCS SDN, Naples, Italy
Search for other papers by Carolina Di Somma in
Google Scholar
PubMed
APHP, Department of Endocrinology and Reproductive Diseases, Bicêtre Paris-Saclay Hospital, Le Kremlin-Bicêtre, France
Paris Sud – Paris Saclay University, Faculté de Médecine, Le Kremlin-Bicêtre, France
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
APHP, Department of Molecular Genetics, Pharmacogenetics and Hormonology, Bicêtre Paris-Saclay Hospital, Le Kremlin-Bicêtre, France
Search for other papers by Séverine Trabado in
Google Scholar
PubMed
Hôpital Necker EnfantsMalades APHP, INSERM U1151, Paris, France
Search for other papers by Dominique Prié in
Google Scholar
PubMed
Search for other papers by Christelle Audrain in
Google Scholar
PubMed
Search for other papers by Anna Barosi in
Google Scholar
PubMed
Search for other papers by Christèle Kyheng in
Google Scholar
PubMed
APHP, Department of Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
APHP, Department of Adolescent Medicine, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
Search for other papers by Anne-Sophie Lambert in
Google Scholar
PubMed
APHP, Department of Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
Paris Sud – Paris Saclay University, Faculté de Médecine, Le Kremlin-Bicêtre, France
Search for other papers by Agnès Linglart in
Google Scholar
PubMed
leads to the upregulation of the expression of phosphaturic fibroblast growth factor 23 (FGF23) in bone, which is secreted in the plasma and induces renal phosphate-wasting hypophosphatemia and low levels of calcitriol (1,25(OH) 2 D) via inhibition of
Search for other papers by Stan Ursem in
Google Scholar
PubMed
Search for other papers by Vito Francic in
Google Scholar
PubMed
Search for other papers by Martin Keppel in
Google Scholar
PubMed
Search for other papers by Verena Schwetz in
Google Scholar
PubMed
Search for other papers by Christian Trummer in
Google Scholar
PubMed
Search for other papers by Marlene Pandis in
Google Scholar
PubMed
Search for other papers by Felix Aberer in
Google Scholar
PubMed
Search for other papers by Martin R Grübler in
Google Scholar
PubMed
Search for other papers by Nicolas D Verheyen in
Google Scholar
PubMed
Search for other papers by Winfried März in
Google Scholar
PubMed
Search for other papers by Andreas Tomaschitz in
Google Scholar
PubMed
Search for other papers by Stefan Pilz in
Google Scholar
PubMed
Search for other papers by Barbara Obermayer-Pietsch in
Google Scholar
PubMed
Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, Amsterdam, Netherlands
Search for other papers by Annemieke C Heijboer in
Google Scholar
PubMed
- and inter-assay coefficients of variation were <5.1 and <7.4%, respectively. FGF23 was measured by a multi-matrix ELISA (FGF23 (C-terminal) ELISA; Biomedica Medizinprodukte GmbH & CO KG, Vienna, Austria). The intra-assay and inter-assay coefficients of
Search for other papers by Fernanda A Correa in
Google Scholar
PubMed
Search for other papers by Ericka B Trarbach in
Google Scholar
PubMed
Search for other papers by Cintia Tusset in
Google Scholar
PubMed
Search for other papers by Ana Claudia Latronico in
Google Scholar
PubMed
Search for other papers by Luciana R Montenegro in
Google Scholar
PubMed
Search for other papers by Luciani R Carvalho in
Google Scholar
PubMed
Search for other papers by Marcela M Franca in
Google Scholar
PubMed
Search for other papers by Aline P Otto in
Google Scholar
PubMed
Search for other papers by Everlayny F Costalonga in
Google Scholar
PubMed
Search for other papers by Vinicius N Brito in
Google Scholar
PubMed
Search for other papers by Ana Paula Abreu in
Google Scholar
PubMed
Search for other papers by Mirian Y Nishi in
Google Scholar
PubMed
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Ivo J P Arnhold in
Google Scholar
PubMed
Search for other papers by Yisrael Sidis in
Google Scholar
PubMed
Search for other papers by Nelly Pitteloud in
Google Scholar
PubMed
Search for other papers by Berenice B Mendonca in
Google Scholar
PubMed
also involved in angiogenesis and neuronal migration (7) . Loss-of-function mutations in FGFR1 and PROKR2 are classically associated with IHH and/or KS (8, 9, 10, 11, 12) . Furthermore, mutations in FGFR1 , PROKR2 and FGF8 , the FGFR1 ligand
Department of Clinical Chemistry, Hematology and Immunology, Noordwest Ziekenhuis, Alkmaar, The Netherlands
Search for other papers by Niek F Dirks in
Google Scholar
PubMed
Search for other papers by Etienne Cavalier in
Google Scholar
PubMed
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Amsterdam UMC location University of Amsterdam, Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam, The Netherlands
Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands
Search for other papers by Annemieke C Heijboer in
Google Scholar
PubMed
tightly regulated by parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), calcium, phosphate, and 1,25(OH) 2 D itself. PTH upregulates the expression of 1α-hydroxylation, while FGF23 and 1,25(OH) 2 D downregulate its expression. Apart from renal
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, University Regional Hospital of Patras, Rio, Greece
Mount Auburn Hospital, Harvard Medical School Teaching Hospital, Cambridge, Massachusetts, USA
Search for other papers by M I Stamou in
Google Scholar
PubMed
Search for other papers by P Varnavas in
Google Scholar
PubMed
Search for other papers by L Plummer in
Google Scholar
PubMed
Search for other papers by V Koika in
Google Scholar
PubMed
Search for other papers by N A Georgopoulos in
Google Scholar
PubMed
such genes include ANOS1 – Anosmin 1, previously known as KAL1 – Kallmann 1, NSMF – NMDA receptor synaptonuclear signaling and neuronal migration factor, FGFR1 – fibroblast growth factor receptor 1 , FGF8 – fibroblast growth factor 8, FGF17
Search for other papers by Maria Mizamtsidi in
Google Scholar
PubMed
Search for other papers by Constantinos Nastos in
Google Scholar
PubMed
Search for other papers by George Mastorakos in
Google Scholar
PubMed
Search for other papers by Roberto Dina in
Google Scholar
PubMed
Search for other papers by Ioannis Vassiliou in
Google Scholar
PubMed
Search for other papers by Maria Gazouli in
Google Scholar
PubMed
Search for other papers by Fausto Palazzo in
Google Scholar
PubMed
pHPT include vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), transforming growth factor beta (TGFβ) and insulin growth factor-1 (IGF-1) ( 43 ). Genes affecting growth factor expression are found to be involved in sporadic pHPT
Search for other papers by Clara Lundetoft Clausen in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Search for other papers by Trine Holm Johannsen in
Google Scholar
PubMed
Search for other papers by Linda Maria Hilsted in
Google Scholar
PubMed
Search for other papers by Niels Erik Skakkebæk in
Google Scholar
PubMed
Search for other papers by Pal Bela Szecsi in
Google Scholar
PubMed
Search for other papers by Lise Pedersen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Thomas Benfield in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Anders Juul in
Google Scholar
PubMed
ligand superfamily member 5 (CD40 ligand/TNFSF5); fractalkine (CX3CL1); growth regulated oncogene-α (CXCL1/GROA/KC/CINC-1); GROB (CXCL2/MIP2/CINC3); interferon-inducible protein 10 (CXCL10/IP10/CRG2); EGF; fibroblast growth factor (FGF basic/FGF2/bFGF
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Christine Rode Andreasen in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Andreas Andersen in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Filip Krag Knop in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
development, and their therapeutic potential for the treatment of T2D and obesity is being investigated in clinical trials ( 55 , 90 , 91 , 92 ). Also, the combination of GLP-1RA with cholecystokinin (CCK) and fibroblast growth factor 21 (FGF21) has been
Search for other papers by Jordyn Silverstein in
Google Scholar
PubMed
Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California, USA
Search for other papers by Wesley Kidder in
Google Scholar
PubMed
Search for other papers by Susan Fisher in
Google Scholar
PubMed
Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA
Search for other papers by Thomas A Hope in
Google Scholar
PubMed
Search for other papers by Samantha Maisel in
Google Scholar
PubMed
Department of Pathology, University of California, San Francisco, California, USA
Search for other papers by Dianna Ng in
Google Scholar
PubMed
Search for other papers by Jessica Van Ziffle in
Google Scholar
PubMed
Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California, USA
Search for other papers by Chloe E Atreya in
Google Scholar
PubMed
Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California, USA
Search for other papers by Katherine Van Loon in
Google Scholar
PubMed
.R122W, FAT1 p.I895T, PREX2 p.H1009L, FGF14 amplification, RB1 amplification, FLT1 amplification, SMO p.V129I BRCA1 p.R496C, GNAS p.P345R,P349_I357del, RB1 amplification, BRCA2 amplification, CDK8 amplification, IRS2 amplification, KDR p.A20T, ZNF703 p